|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:acquisition
|
gptkb:Impact_Biomedicines
gptkb:Juno_Therapeutics
Acquired by Bristol-Myers Squibb in 2019
|
|
gptkbp:acquisition_year
|
gptkb:2019
|
|
gptkbp:advertising
|
gptkb:David_N._Elkins
|
|
gptkbp:clinical_trial
|
gptkb:Oncology
gptkb:CAR_T-cell_therapy
ongoing
collaborative studies
clinical trials for new drugs
|
|
gptkbp:community_engagement
|
gptkb:healthcare_professionals
patient advocacy
research institutions
|
|
gptkbp:conducts_research_on
|
gptkb:Alfred_Sandrock
|
|
gptkbp:employees
|
7,000 (2019)
7,000 (2018)
|
|
gptkbp:fda_approvals
|
Pomalyst (2013)
Revlimid (2005)
Thalomid (1998)
|
|
gptkbp:financial_performance
|
high profit margins
strong revenue growth
consistent earnings growth
|
|
gptkbp:founded
|
gptkb:1986
|
|
gptkbp:founder
|
gptkb:Sol_J._Barer
|
|
gptkbp:global_presence
|
operates in over 70 countries
|
|
gptkbp:governance
|
gptkb:Board_of_Directors
shareholder engagement
executive compensation policies
|
|
gptkbp:head_of_state
|
gptkb:Scott_Smith
|
|
gptkbp:headquarters
|
gptkb:Summit,_New_Jersey
gptkb:United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Celgene Corporation
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:innovation
|
focus on novel therapies
investment in R& D
|
|
gptkbp:key_people
|
gptkb:Jacqualyn_A._Fouse
gptkb:Mark_J._Alles
gptkb:Robert_J._Hugin
|
|
gptkbp:leadership
|
diverse leadership team
|
|
gptkbp:market_cap
|
$74 billion (2018)
|
|
gptkbp:marketing_strategy
|
global expansion
therapeutic area focus
|
|
gptkbp:part_of
|
gptkb:Bristol-Myers_Squibb_Company
|
|
gptkbp:partnership
|
gptkb:Agios_Pharmaceuticals
gptkb:Celyad
gptkb:Zymeworks
gptkb:Takeda_Pharmaceutical_Company
gptkb:Iovance_Biotherapeutics
gptkb:Kite_Pharma
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Juno_Therapeutics
gptkb:Pfizer
gptkb:Sangamo_Therapeutics
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Eli_Lilly_and_Company
gptkb:Vertex_Pharmaceuticals
gptkb:Abb_Vie
gptkb:Cure_Vac
gptkb:Novartis
gptkb:Nant_Kwest
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
gptkb:Janssen_Pharmaceuticals
gptkb:Amgen
gptkb:Abb_Vie
|
|
gptkbp:philanthropy
|
gptkb:Celgene_Foundation
|
|
gptkbp:products
|
gptkb:Revlimid
gptkb:Pomalyst
gptkb:Thalomid
|
|
gptkbp:regulatory_compliance
|
adheres to EMA regulations
adheres to FDA regulations
|
|
gptkbp:research_focus
|
gptkb:Oncology
oncology
hematology
immunology
inflammatory diseases
|
|
gptkbp:revenue
|
$15.2 billion (2019)
$4.2 billion (2018)
|
|
gptkbp:stock_symbol
|
gptkb:CELG
|
|
gptkbp:subsidiaries
|
gptkb:Celgene_Cellular_Therapeutics
gptkb:Celgene_International_Sàrl
|
|
gptkbp:subsidiary
|
gptkb:Celgene_Cellular_Therapeutics
|
|
gptkbp:sustainability_initiatives
|
community support programs
environmental responsibility
employee engagement programs
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.celgene.com
|
|
gptkbp:bfsParent
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:bfsLayer
|
4
|